Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs

– Strong global pipeline progress – three U.S. FDA1Fast Track Designations; surufatinib U.S. NDA2preparations underway; and initiation of global Phase III for fruquintinib –